This will be a phase 1, randomised, single blinded dose escalation study in healthy adult volunteers. There will be three groups of 6 volunteers receiving increasing doses of the MAb. 0.125g dose group , the 0.25g dose group and the 0.5g dose group The volunteers will be followed up for 3 months post dose when safety and immunogenicity will be assessed.